Income statement
CAD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 554K | 806K | 827K | 0 | 0 |
| Gross Profit | 318K | 382K | 274K | 0 | 0 |
| Operating Income | -339K | -1M | -5M | -2M | -2M |
| EBITDA | -266K | -1M | -5M | -2M | 0 |
| Net Income | -420K | -1M | -5M | -2M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0002
+0.00% today
1Y Change
-50.00%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 252 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Street Capital Inc. (REZNF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 50.0% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -31.2%, EPS growth of +70.0%, a dividend yield of 0.0%. What stands out right now is revenue -31.2%, EPS +70.0%, free cash flow +95.8% with operating margin -48.0% and ROIC 207.3%. Valuation is more restrained than many high-expectation growth names at price/sales 2.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines REZNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REZNF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
REZNF Max Drawdown
-98.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for REZNF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.0M
-1.0% YoY
Free Cash Flow
-$378.1K
+63.2% YoY
Revenue Growth
-31.2%
EPS Growth
+70.0%
Gross Margin
57.4%
Net Margin
-75.8%
Income statement
CAD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 554K | 806K | 827K | 0 | 0 |
| Gross Profit | 318K | 382K | 274K | 0 | 0 |
| Operating Income | -339K | -1M | -5M | -2M | -2M |
| EBITDA | -266K | -1M | -5M | -2M | 0 |
| Net Income | -420K | -1M | -5M | -2M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25K | 40K | 354K | 2M | 3M |
| Total Assets | 262K | 504K | 1M | 2M | 3M |
| Total Liabilities | 658K | 516K | 242K | 225K | 252K |
| Shareholder Equity | -396K | -12K | 1M | 2M | 2M |
| Total Debt | 268K | 219K | 41K | 0 | 0 |
| Net Debt | 243K | 179K | -313K | -2M | -3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
378K
+58.2% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
378K
+63.2% YoY
Key ratios
Gross Margin
57.4%
Operating Margin
-48.0%
Net Margin
-75.8%
ROE
205.5%
Debt / Equity
-0.68x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.